Arrowhead Pharmaceuticals Inc (ARWR) Options

Should be a good Tuesday
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-presents-pivotal-phase-103600472.html

ARWR over $20

CEO speaks
https://www.biotechtv.com/post/arrowhead-pharmaceuticals-february-1-2024

I'm new to all of this and perhaps it shows, but if I understand this correctly, CNTX reports enough $$ (only) to carry them through the end of '24. Seems a pretty large caveat...

ARWR was beaten down once and here is another one

Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)

(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.


Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened. 

Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share.  ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to  Viking Therapeutics it had the same beat down before running up to over $25 a share.  In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023.  Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.

Due your own research and the wise will should agree.

ARWR still ascending.
Entered yesterday.
I added 40% more this morning on the strength of the chart
Average is 36.17
1/19 Data Report date
Limited DD
https://stockcharts.com/h-sc/ui?s=ARWR

Arrowhead is an amazing company. Gene silencing is a world away from gene editing.

NEWS: $ARWR Why Arrowhead Pharmaceuticals Stock Jumped Today

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) rose sharply on Thursday and closed today's trading session up 9.9% after climbing by as much as 14.4%. The drugmaker did not report any news, but biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX) released an update regardin...

In case you are interested ARWR - Why Arrowhead Pharmaceuticals Stock Jumped Today

* * $ARWR Video Chart 09-16-2020 * *

Link to Video - click here to watch the technical chart video

ARWR $weet upside run....check out QRTEB > nice upside as well.

Lucky folks that own IPO shares of SNOW > $$$$$

great gapper this one today

Arrowhead Pharmaceuticals shares are trading higher after the company announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company's second-generation investigational RNA interference therapeutic.

ARWR

ARWR MOVING VERY SWIFTLY TOO FOR A STOCK WITH 102M SHARES

Breaking News: $ARWR Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment

- Up to 97% reduction in intra-hepatic Z-AAT polymer - Up to 95% reduction in intra-hepatic total Z-AAT burden - Up to 66% and 58% reduction in circulating ALT and GGT levels respectively - Up to 26% improvement in FibroScan values Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)...

Find out more ARWR - Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment

guess you got your wish

Lurking for entry sub $40...eom

Happy options expirations day!

http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-doses-first-patient-aroaat2002-open

No changes in the company besides positive. Has to be manipulation, imo. All good after options expire Friday.

So its down sharply on good news?

http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-regulatory-clearance-begin-4

That is sad.
Companies that used them should take responsibility for their care. The gov. should compel them to.

BTW. The drugs used must have been good. According to the article they were dumped there since the 70s. ARWR wasn't around then, I think.

I'm no ARWR millionaire yet, but yes, these chimps need some fruits, nuts etc. I know a lot of them at yahoo board. Uhh… some millionaires too.

Looks like there will be a lot more of them shortly. ARWR may head higher. She will be flying high in the SP 400 midcap soon. So come on brudahs! Kokua! Malama!

I am keeping the link just in case... Aloha!

$ARWR upgraded to S&P MidCap 400 index starting 12/23

https://twitter.com/sonichedgefund/status/1205616137582460928?s=19

Liberia’s Monkey Island, Charity
As there are now a few “ARWR millionaires” on this board please consider making a donation to The Humane Society to benefit Liberia’s Monkey Island. These chimps are for lab testing subjects that have been abandoned on an island with little to no food they can gather for themselves. They rely on people bringing them food. A portion of the chimp population was used for Hepatitis B testing. Some of the “ARWR millionaires” bought shares at absurdly low prices in part due to ARWR proving that ARC-520 could knock down HBsAg in HBV infected chimps. Read more details below and keep the link incase you need to send it to a Humane Society rep to describe where you want your money to go to:

https://m.greenwichtime.com/news/article/U-S-lab-chimps-were-dumped-on-Liberia-s-Monkey-14901091.php

I can’t post this to Y!Finance and I don’t have Twitter at the moment so if you want to spread this around, be my guest. The Chimps need to collect their dividend!

link to donate
https://www.liberiachimps.org/donate?utm_source=syndication&s_src=mr_mr_liberiadonate12122019&credit=mr&utm_campaign=liberia_chimps&utm_medium=mr

$ARWR bears are running Arrowhead Pharmaceuticals Inc Nasdaq Arwr Short Squeeze

Nice pennant formation.

Targets?
Base $52 73-52=21 21+73=$94!
Base $42 73-42=31 31+73=$104!?

need to break 73

News: $ARWR Here's Why Arrowhead Pharmaceuticals Is Soaring Today

Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) gained as much as 14.4% today after the company announced a public stock offering. It seems counterintuitive, but investors appear to be excited about a snippet of text listing possible uses for the proceeds. The company made the standard e...

In case you are interested ARWR - Here's Why Arrowhead Pharmaceuticals Is Soaring Today

News: $ARWR Don't Waste Your Money on Penny Stocks; These 3 Companies Are Better Buys

There's a certain excitement to buying penny stocks and being able to control a large number of shares with comparatively little cash outlay. Even small movements in the share price can generate substantial returns. But penny stocks rarely give investors such opportunities, and most turn into b...

Got this from ARWR - Don't Waste Your Money on Penny Stocks; These 3 Companies Are Better Buys

Looks like a lot of people got whipsawed.
Now they are looking to get back their positions.

Hanging tight on this stock seems to be a good strategy.
The science is cutting edge. A buyout is in the calendar but then a secondary changes that. imo.

A secondary was also a way for the shorts to escape.

It’s down 5% more in after hours from a secondary announcement

Wow... that's a haircut.

Arwr is doing close to 45 million in revenue each quarter.
I do think a PE of 105 is far ahead of itself

I think qbio is going to do that within a year .(2021)
You do the math.only 16.7 million shares there ,ARWR 95 millon shares

Commercialization of product 2020
product going into phase 2-3 2020
possible uplisting nasdaq 2020

I think it can for sure.

They got great products ,one commercialization in 2020 .
That is a potential 500 million in revenue within 2-3 years
Because it's a proven product and know by doctors that are facing patients with bonecancer . could be used for other painrelief then that.

Also there autistic orphandrug is about to go in phase 2-3
If so even in the trials it's worth a lot of money.
potential 2 billion in revenue.

Also the mannin divison in europe has got a grant from the government .
governments are conservative ,when you throw 7.5 million $ at it you almost know this is going to make it.

There was recent interest in mannin by big pharma accoring to the ceo.

Qbio could indeed be the next ARWR.

Also a big positive is the amazing share structure

Can QBIO end up as high as this stock one day?

it's likely headed to a market cap of $9.7 Billion. The buyout price of MDCO. I think it's doable. ARWR has better pipeline than them.

I need to send someone a fruit basket... Should have bought more.....

Another increased PT. $81.00/share

https://www.analystratings.com/articles/arrowhead-research-arwr-receives-a-buy-from-chardan-capital/?ref=tipranks

Okay junior... Don't forget to have fun! while at it.
Happy Thanksgiving.

News: $ARWR What Happened in the Stock Market Today

Real estate and consumer stocks lifted the major benchmarks on Tuesday, with the  Dow Jones Industrial Average (DJINDICES: ^DJI)  and the  S&P 500 (SNPINDEX: ^GSPC)  closing at record highs. Earnings reports generally supported a positive view of the U.S. consumer, bu...

Read the whole news ARWR - What Happened in the Stock Market Today

News: $ARWR Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Jaffray 31st Annual Healthcare Conference – New York, December 3-5, 2019 December 3, 11:00 a.m. EST – Chris Anzalone, Ph.D., Arro...

Got this from ARWR - Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences

News: $ARWR Here's Why Arrowhead Pharmaceuticals Is Soaring (Again) Today

Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) jumped as much as 18.1% today after the company reported fiscal full-year 2019 operating results. Arrowhead Pharmaceuticals is a pre-commercial company, but operations have been solidly profitable thanks to a collaboration with Johnson &...

In case you are interested ARWR - Here's Why Arrowhead Pharmaceuticals Is Soaring (Again) Today

Ahhh!
what happiness
As the night rain passes
And the seedlings burst forth.

News: $ARWR Arrowhead Research Corp (ARWR) Q4 2019 Earnings Call Transcript

Image source: The Motley Fool. Arrowhead Research Corp   (NASDAQ: ARWR) Q4 2019 Earnings Call Nov 25, 2019 , 4:30 p.m. ET Operator Continue reading

Find out more ARWR - Arrowhead Research Corp (ARWR) Q4 2019 Earnings Call Transcript

* * $ARWR Video Chart 11-25-2019 * *

Link to Video - click here to watch the technical chart video

News: $ARWR Why Lyft, Arrowhead Pharmaceuticals, and Ferro Jumped Today

Monday was a solid day for the major benchmarks. Investors liked what they saw coming out of China, as well as on the mergers and acquisitions front. As the key holiday shopping season approaches, market participants hope that the U.S. consumer will continue to support economic growth into 2020....

In case you are interested ARWR - Why Lyft, Arrowhead Pharmaceuticals, and Ferro Jumped Today

News: $ARWR Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results

- Conference Call and Webcast Today at 4:30 p.m. EST Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2019. The company is hosting a conference call at 4:30 p.m. EST to discuss results. Conference Call and Webcas...

In case you are interested ARWR - Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results

9, count’em , NINE major real ceiling busters in the pipeline today this morning, I was up $42,000 in one day on this bad boy!!!
I am new to this board, just thought I would take a look at IHUB on ARWR. YAHOO..... Take a look at news on yahoo about this one!!
TKO

Nice!

$ARWR Robert W. Baird Upgrades Arrowhead Pharmaceuticals (ARWR) $49.20 $70.00 Neutral ? Outperform

Va-Booom! $55.
This is crazy.
Good kind of crazy.

Bummers man!...

I bought 10k shares average at six buck$ about 4-5 years ago.. Watched in horror as it dove down to around $buck and a half. They stopped a couple of clinical trials -their DPC wasn't good. Too disgusted to even look at it for a long time but held.

Things changed when they switched to TRIM.